Ann: Results of Phase 2 Clinical Trial, page-97

It's not bad advice if you think about it. Market cap is about $2m with cash of $2m. They will be entitled to an R&D refund and the burn is going to be low. It could do ok if they were to announce a deal/RTO etc.

I just bought more (not advocating others to but my parcel was small and I was able to increase it significantly with a reasonably small outlay). Biotechs generally tend to have a massive overreaction on negative news so hoping it bounces tomorrow. Doubt it will go up that quickly but we'll see.

I definitely agree with super that it is worth a punt on the shell alone. That's all I seem to be investing in (shells) at the moment ​